Deep vein thrombosis: pathogenesis, diagnosis, and medical management.

Deep vein thrombosis (DVT) is a major preventable cause of morbidity and mortality worldwide. Venous thromboembolism (VTE), which includes DVT and pulmonary embolism (PE), affects an estimated 1 per 1,000 people and contributes to 60,000-100,000 deaths annually. Normal blood physiology hinges on a delicate balance between pro- and anti-coagulant factors. Virchow's Triad distills the multitude of risk factors for DVT into three basic elements favoring thrombus formation: venous stasis, vascular injury, and hypercoagulability. Clinical, biochemical, and radiological tests are used to increase the sensitivity and specificity for diagnosing DVT. Anticoagulation therapy is essential for the treatment of DVT. With few exceptions, the standard therapy for DVT has been vitamin K-antagonists (VKAs) such as warfarin with heparin or fractionated heparin bridging. More recently, a number of large-scale clinical trials have validated the use of direct oral anticoagulants (DOACs) in place of warfarin in select cases. In this review, we summarize the pathogenesis, diagnosis, and medical management of DVT, with particular emphasis on anticoagulation therapy and the role of DOACs in the current treatment algorithm.

[1]  E. Husni Pathogenesis of venous thrombosis. , 1971, JAMA.

[2]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[3]  G. Raskob,et al.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.

[4]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[5]  M. Armon,et al.  Thrombolysis for acute deep vein thrombosis , 1996, The Cochrane database of systematic reviews.

[6]  S. Wicky,et al.  Efficacy of Lower-Extremity Venous Thrombolysis in the Setting of Congenital Absence or Atresia of the Inferior Vena Cava , 2012, CardioVascular and Interventional Radiology.

[7]  F. Rybicki,et al.  ACR Appropriateness Criteria(®) on suspected lower extremity deep vein thrombosis. , 2011, Journal of the American College of Radiology : JACR.

[8]  T. Ortel,et al.  Venous thromboembolism: a public health concern. , 2010, American journal of preventive medicine.

[9]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[10]  S. Wicky,et al.  Catheter-Directed Thrombolysis of Deep Venous Thrombosis , 2013, Seminars in Thrombosis & Hemostasis.

[11]  G. Stansby,et al.  The management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE Guideline CG144. , 2012, Acute medicine.

[12]  Adnan Memić,et al.  Pathogenesis of Thromboembolism and Endovascular Management , 2017, Thrombosis.

[13]  C. Esmon Basic mechanisms and pathogenesis of venous thrombosis. , 2009, Blood reviews.

[14]  A. Nicolaides,et al.  The origin of deep vein thrombosis: a venographic study. , 1971, The British journal of radiology.

[15]  R. Bertina Elevated Clotting Factor Levels and Venous Thrombosis , 2003, Pathophysiology of Haemostasis and Thrombosis.

[16]  W M O'Fallon,et al.  Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. , 1998, Archives of internal medicine.

[17]  T. Baglin,et al.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[18]  S. Yale,et al.  Virchow’s Contribution to the Understanding of Thrombosis and Cellular Biology , 2010, Clinical Medicine & Research.

[19]  L. Tamariz,et al.  Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs. , 2003, The American journal of medicine.

[20]  R. White,et al.  The epidemiology of venous thromboembolism. , 2003, Circulation.

[21]  R. Gans,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2011, The New England journal of medicine.

[22]  F. Sampson,et al.  The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis , 2006, European Radiology.

[23]  P. Cancilla,et al.  Use of endothelium cultured on microcarriers as a model for the microcirculation. , 1982, Laboratory investigation; a journal of technical methods and pathology.

[24]  Steve Goodacre,et al.  Bmc Medical Imaging Systematic Review and Meta-analysis of the Diagnostic Accuracy of Ultrasonography for Deep Vein Thrombosis , 2005 .

[25]  L. Sandvik,et al.  Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial , 2012, The Lancet.

[26]  Y. Loke,et al.  Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta‐analysis and adjusted indirect comparison , 2014, British journal of clinical pharmacology.

[27]  J. Julian,et al.  Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. , 1998, Annals of internal medicine.

[28]  G. Raskob,et al.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.

[29]  S. Wicky,et al.  Catheter-Directed Thrombolysis of Arterial Thrombosis , 2013, Seminars in Thrombosis & Hemostasis.

[30]  A. Dans,et al.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[31]  C. Kearon,et al.  Natural History of Venous Thromboembolism , 2003, Circulation.

[32]  J. McLachlin,et al.  Precipitating factors in venous thrombosis. , 1954, Surgery, gynecology & obstetrics.

[33]  Gordon H. Guyatt,et al.  Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis , 2011 .

[34]  Jonathan Dreyer,et al.  Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. , 2003, The New England journal of medicine.

[35]  C. Esmon,et al.  Valves of the deep venous system: an overlooked risk factor. , 2007, Blood.

[36]  F. Belloc,et al.  Influence of hypoxia and hypoxia-reoxygenation on endothelial P-selectin expression. , 1996, Haemostasis.

[37]  Giancarlo Agnelli,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.

[38]  S. Goldhaber,et al.  Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis , 2014, Circulation.

[39]  Adam Torbicki,et al.  Management of venous thrombo-embolism: an update. , 2014, European heart journal.

[40]  R. Lopes,et al.  Guidance for the treatment of deep vein thrombosis and pulmonary embolism , 2016, Journal of Thrombosis and Thrombolysis.

[41]  F. Rosendaal,et al.  Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use , 2003, Thrombosis and Haemostasis.

[42]  I. Silver,et al.  The PO2 in venous valve pockets: Its possible bearing on thrombogenesis , 1981, The British journal of surgery.

[43]  E. Horváth-Puhó,et al.  30-Year Mortality After Venous Thromboembolism: A Population-Based Cohort Study , 2014, Circulation.

[44]  Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[45]  S Sevitt,et al.  The structure and growth of valve-pocket thrombi in femoral veins , 1974, Journal of clinical pathology.

[46]  D. Lamping,et al.  Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. , 2008, Annals of internal medicine.

[47]  F. Sampson,et al.  Diagnostic value of CT for deep vein thrombosis: results of a systematic review and meta-analysis. , 2008, Clinical radiology.

[48]  L. Rao,et al.  Tissue factor as a tumor procoagulant , 1992, Cancer and Metastasis Reviews.

[49]  K. Rabinov,et al.  Roentgen diagnosis of venous thrombosis in the leg. , 1972, Archives of surgery.

[50]  John A. Heit,et al.  The epidemiology of venous thromboembolism , 2003, Journal of Thrombosis and Thrombolysis.

[51]  M. C. Sheps,et al.  Biologic assay of a thrombosis-inducing activity in human serum. , 1959, Journal of applied physiology.

[52]  Chad J Zack,et al.  Comparative outcomes of catheter-directed thrombolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal deep vein thrombosis. , 2014, JAMA internal medicine.

[53]  Young Hwan Kim,et al.  Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines , 2016, Vascular specialist international.

[54]  Adrian V. Hernández,et al.  Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. , 2012, Archives of internal medicine.

[55]  Jason C. Fish,et al.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[56]  Wendy Lim,et al.  The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. , 2014, Blood.

[57]  Susan Regan,et al.  Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. , 2003, Archives of internal medicine.

[58]  D. Wagner,et al.  P-selectin and leukocyte microparticles are associated with venous thrombogenesis. , 2003, Journal of vascular surgery.

[59]  J. Ericsson,et al.  Postmortem Intraosseous Phlebography as an Aid in Studies of Venous Thromboembolism , 1969, Angiology.

[60]  M. Math,et al.  Noninvasive Diagnosis of Deep Venous Thrombosis , 1998, Annals of Internal Medicine.

[61]  M. Watkins,et al.  Detection of extracellular genomic DNA scaffold in human thrombus: implications for the use of deoxyribonuclease enzymes in thrombolysis. , 2012, Journal of vascular and interventional radiology : JVIR.

[62]  F. Rosendaal Venous thrombosis: a multicausal disease , 1999, The Lancet.

[63]  F. García-Bragado Dalmau [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism]. , 2013, Revista clinica espanola.

[64]  M. Watkins,et al.  Reduced hind limb ischemia-reperfusion injury in Toll-like receptor-4 mutant mice is associated with decreased neutrophil extracellular traps. , 2013, Journal of vascular surgery.

[65]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[66]  S. Doucette,et al.  Does this patient have deep vein thrombosis? , 1998, JAMA.

[67]  Janis Bormanis,et al.  Value of assessment of pretest probability of deep-vein thrombosis in clinical management , 1997, The Lancet.

[68]  S. Kahn,et al.  Postthrombotic syndrome: a 2014 update , 2014, Current opinion in cardiology.

[69]  N. Abraham,et al.  Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study , 2015, BMJ : British Medical Journal.